Algernon Pharmaceuticals Salt Patent as Part of its Psychedelic Drug DMT Intellectual Property
Andrew O’Donnel is joined by Chrostoph J. Moreau, CEO of Algernon Pharmaceuticals. CSE: AGN
Algernon Pharmaceuticals is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Christopher J. Moreau
Chief Executive Officer
Mr. Moreau is a seasoned business professional in the life sciences sector with a strong background in biotechnology research, business development and a deep expertise in the capital markets. Mr. Moreau was previously President & CEO and Director of a publicly traded company focussed on the research & development of screening tests for prostate cancer, skin cholesterol and type 2 diabetes. He has raised in excess of $30 million from the capital markets and has over 30 years of senior management experience in private & publicly traded company environments.
THE MARKET MINDSET
Our goal is to help you feel comfortable stepping into the stock market and are giving you free hot tips every day!
Join us on twitter to get our DAILY live video market updates